• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    DIAGNOS Announces a New Partner in Cambodia

    Bryan Mc Govern
    Oct. 17, 2017 09:10AM PST
    Biotech Investing

    DIAGNOS announced the addition of a new medical partner, Garuda Health Services, to cover the country of Cambodia.

    DIAGNOS (TSXV:ADK; OTCQB:DGNOF) announced the addition of a new medical partner, Garuda Health Services, to cover the country of Cambodia.
    As quoted in the press release:

    Garuda Health Services (GHS) first customer will be Royal Phnom Penh Hospital. A new screening service will be offered to their clientele at their annual physical exam. The service is scheduled to be launched in late fall of this year and should cover 22,400 patients under their care. DIAGNOS’ CARA solution will provide automatic detection and classification of Diabetic Retinopathy disease. Detection of anomalies for AMD (Age Macular Degeneration) is also planned to be available. In early 2018, CARA Cardio is scheduled to be added as a new screening service for cardio vascular diseases.
    “In adding eye screening with retina anomalies detection, we are increasing the number of health points to better determine the global health of our patients. This will significantly help us to prevent disease evolution and take early action. As DIAGNOS is developing new algorithms to detect more illness, we will be ready to use them.

    Click here to read the full press release.

    Source: www.marketwired.com

    The Conversation (0)

    Go Deeper

    AI Powered
    Doctor looking into a microscope

    5 Small Medical Device Companies

    Cleo Diagnostics CEO Richard Allman.

    Cleo Diagnostics Revolutionises Ovarian Cancer Screening with Early Detection

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×